Rafferty Asset Management
PMVP icon

Rafferty Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Rafferty Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-264,772
Closed -$2.3M – 1162
2022
Q4 		$2.3M Sell
264,772
-24,546
-8% -$262K 0.02% 535
2022
Q3 		$3.44M Buy
289,318
+49,454
+21% +$714K 0.04% 392
2022
Q2 		$3.42M Buy
239,864
+67,764
+39% +$986K 0.03% 362
2022
Q1 		$3.58M Buy
172,100
+53,906
+46% +$951K 0.02% 461
2021
Q4 		$2.73M Buy
118,194
+38,745
+49% +$936K 0.01% 560
2021
Q3 		$2.37M Buy
79,449
+44,735
+129% +$1.43M 0.02% 587
2021
Q2 		$1.19M Buy
34,714
+8,242
+31% +$275K 0.01% 825
2021
Q1 		$871K Buy
+26,472
New +$1.04M 0.01% 805

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rafferty Asset Management's PMVP Position: Q1 2023 in Review

Rafferty Asset Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2023, closing a stake of 264,772 shares — an estimated $2.3M sold.

Rafferty Asset Management first reported a position in PMVP in Q1 2021 and held it in 8 quarters. The position peaked at $3.58M in Q1 2022. 111 funds tracked by Wall St. Rank hold PMVP as of Q1 2023.

  • Rafferty Asset Management reported no remaining PMV Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 264,772 PMV Pharmaceuticals shares in Q1 2023, an estimated $2.3M.
  • Rafferty Asset Management first reported a position in PMV Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Rafferty Asset Management's PMV Pharmaceuticals position peaked at $3.58M in Q1 2022.
  • 111 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2023.

Based on Rafferty Asset Management's 13F filing for Q1 2023, filed 11 May 2023.